Organovo

FXR314, is Organovo’s lead therapeutic molecule. FXR314 demonstrated benefit to ulcerative colitis in Organovo’s models of disease as well as extensive preclinical testing. It has shown, in initial clinical trials, to be a possible best-in-class FXR agonist that is delivered orally, with high potency, safety, tolerability and the potential to avoid dose-limiting toxicity issues found in other FXR targeted compounds.

Basic Information

Evidence and Sources

Citation Guidance

Explore biotechnology profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Organovo.

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

FXR314, is Organovo’s lead therapeutic molecule. FXR314 demonstrated benefit to ulcerative colitis in Organovo’s models of disease as well as extensive preclinical testing. It has shown, in initial clinical trials, to be a possible best-in-class FXR agonist that is delivered orally, with high potency, safety, tolerability and the potential to avoid dose-limiting toxicity issues found in other FXR targeted compounds.

Available profile information

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.